Treatment with any of several VEGF receptor-targeted tyrosine kinase inhibitors (TKIs) results in prolonged disease stability or even regression in the majority of patients with metastatic renal cell carcinoma (RCC). This antitumor effect is generally transient and incomplete, however, due to the rapid development of drug resistance. This project emerged from our earlier work in RCC xenografts on the mechanisms of acquired TKI resistance. We observed that p53 activation was essential for a robust response to sunitinib. We also noted that the expression of p53-dependent genes was transient and down modulated with the onset of TKI resistance. Finally, we demonstrated that the concurrent administration of a drug that blocks HDM2- dependent p53 ubiquitylation and degradation prevented the development of TKI resistance. At least two potential mechanisms for this effect were documented, one of which involved in the induction of the E3 ligase Fbw7 and the degradation of the oncoprotein HIF-2alpha. Another potential mechanism by which HDM2 antagonists prevent TKI resistance is their ability to block the expression of hypoxia-driven chemokines such as SDF-1 (CXCL-12) and to prevent the influx of CD11b+/Gr-1+ myeloid-derived tumor suppressor cells (MDSC). In this project, we propose to carry out a Phase I/Ib clinical trial examining a combination of sunitinib with the HDM2 antagonist CGM097 (Novartis). This trial will have a 20 patient expansion cohort in which the administration of the HDM2 antagonist will be delayed in half of the patients. Tumor biopsies will be performed on these patients (half of which will be receiving sunitinib alone and half the drug combination at the time of biopsy) to assess the effects of treatment on p53 activation and MDSC and Treg trafficking. We will examine the effects of MDSC depletion on treatment outcome in murine RCC models and will determine if targeting the SDF-1 receptor (CXCR4) with the CXCR4 inhibitor AMD11070 prevents MDSC recruitment and the onset of TKI resistance as effectively as HDM2 blockade. Finally, we will assess the effects of HDM2 blockade on the expression of IL-8, FGF, and other factors previously implicated in the development of TKI resistance

Public Health Relevance

We have demonstrated that drugs that block HDM2-dependent degradation of p53 prevent the development of resistance to VEGFR-targeted TKI therapy in xenograft models of RCC. This project will determine if HDM2 antagonists have a similar effect in RCC patients undergoing TKI treatment and will examine several potential mechanisms of action by which such an additive antitumor effect is achieved

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA101942-15
Application #
9771378
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
15
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Gao, Xin; McDermott, David F (2018) Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. Expert Opin Biol Ther 18:947-957
Gopal, Raj K; Calvo, Sarah E; Shih, Angela R et al. (2018) Early loss of mitochondrial complex I and rewiring of glutathione metabolism in renal oncocytoma. Proc Natl Acad Sci U S A 115:E6283-E6290
Scelo, Ghislaine; Muller, David C; Riboli, Elio et al. (2018) KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case-Control Study. Clin Cancer Res 24:5594-5601
Zhang, Jinfang; Bu, Xia; Wang, Haizhen et al. (2018) Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553:91-95
Gao, Xin; Jegede, Opeyemi; Gray, Connor et al. (2018) Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer 16:341-348
Liu, Wenjing; Chen, Binbin; Wang, Yang et al. (2018) RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism. Proc Natl Acad Sci U S A 115:E1475-E1484
Iorgulescu, J Bryan; Braun, David; Oliveira, Giacomo et al. (2018) Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med 10:87
Gopal, Raj K; Kübler, Kirsten; Calvo, Sarah E et al. (2018) Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell 34:242-255.e5
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Signoretti, Sabina; Flaifel, Abdallah; Chen, Ying-Bei et al. (2018) Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. J Clin Oncol :JCO2018792259

Showing the most recent 10 out of 153 publications